HRS2300

· Jiangsu HengRui Medicine Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for HRS2300, covering 2024-09-19 to 2024-09-19. Get the full timeline:

Most recent: Clinical Trial Update: A Phase I Study of HRS2300 or Combined With SHR-1316 or SHR-1701 or Trametinib or Almonertinib in Patients With Advanced Malignancies [Phase 1]

See pricing